Proseek Bio Research Accepted at ASCO 2026: Demonstrating Reproducibility Across International Laboratories

Proseek Bio is pleased to announce that our research has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world's leading forums for oncology research, clinical practice, and innovation.

The accepted abstract, published in the Journal of Clinical Oncology, reports findings from an international collaboration between Australia and Malaysia. The study highlights the successful completion of an inter-laboratory development study designed to evaluate the transferability, robustness, and reproducibility of Proseek's diagnostic technology across independent sites, as well as the first pilot analysis in an Asian cohort.

Why Reproducibility Matters

In diagnostics, innovation alone is not enough.

A technology may demonstrate promising performance in a single laboratory, but its broader potential depends on whether those results can be reproduced consistently across different environments, operators, and populations.

Reproducibility is an important benchmark in the development of any diagnostic platform. It provides confidence that a test can perform reliably beyond its original research setting and supports future stages of technology development.

For clinicians and researchers, reproducibility builds confidence in the underlying science. For healthcare systems, it supports scalability. For developers, it represents an important milestone on the pathway from scientific discovery to real-world implementation.

Strengthening Global Collaboration

The ASCO-accepted study reflects the importance of international collaboration in advancing innovative diagnostics.

By evaluating Proseek's technology across laboratories in Australia and Malaysia, the study demonstrated consistent performance across independent sites. Importantly, the pilot Malaysian cohort provided early proof-of-concept supporting the applicability of Proseek's biomarkers within Asian populations.

Demonstrating reproducibility across geographies and laboratory settings is an important step in building the evidence base required for future clinical studies, regulatory engagement, and commercialisation activities.

The collaboration also highlights the growing importance of global partnerships in addressing challenges in cancer detection and diagnosis, ensuring technologies are assessed across diverse healthcare settings and populations.

Advancing Earlier Detection in Ovarian Cancer

Proseek Bio is focused on developing diagnostics that support earlier detection and improve clinical decision-making in ovarian cancer.

Despite significant advances in cancer treatment, ovarian cancer continues to be associated with poorer outcomes when diagnosed at later stages. Earlier detection remains one of the most significant opportunities to improve survival and quality of life for women affected by the disease.

Achieving this goal requires not only scientific innovation, but also rigorous development, verification, and evidence generation. Technologies must consistently demonstrate reliable performance and clinical utility as they progress through the development pathway.

Publication of this work in the Journal of Clinical Oncology and its acceptance at ASCO represent important milestones in that journey.

Looking Ahead

This abstract represents an early step in Proseek Bio's broader program of multi-cohort development studies and multi-site evaluations being conducted in collaboration with international partners.

As we continue to expand our research across diverse populations and laboratory settings, our focus remains on generating the robust evidence needed to support future clinical translation and adoption.

We are grateful to our collaborators in Australia and Malaysia for their expertise, partnership, and shared commitment to improving outcomes for women worldwide through earlier detection of ovarian cancer.